SCHEMBL18148653

SCHEMBL18148653

Fc1cccc2c1nc1n2CCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
TP53 P04637 2/20 0.43
L3MBTL1 Q9Y468 3/20 0.40
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
BCHE P06276 1/20 0.40
CFTR P13569 1/20 0.40
ALOX15 P16050 1/20 0.40
ACHE P22303 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GOPC Q9HD26 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
WDR5 P61964 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31037904 0.80 POLB (0.44) POLBTP53L3MBTL1KDM4EUSP2
SCHEMBL30842164 0.80 POLB (0.44) POLBTP53L3MBTL1KDM4EUSP2
SCHEMBL5511715 0.78 ALDH1A1 (0.60) TP53L3MBTL1KDM4EUSP2ALDH1A1
SCHEMBL31546213 0.75 POLB (0.50) POLBTP53ALDH1A1MEN1KMT2A
SCHEMBL31546226 0.75 POLB (0.50) POLBTP53KDM4EALDH1A1HSD17B10
SCHEMBL31037926 0.74 POLB (0.52) POLBTP53ALDH1A1MEN1KMT2A
SCHEMBL20528250 0.74 CCND3 (0.38) TP53ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL31037908 0.74 POLB (0.52) POLBTP53L3MBTL1KDM4EALDH1A1
SCHEMBL8970389 0.73 ACHE (0.50) POLBTP53ALDH1A1ACHEMEN1
SCHEMBL503163 0.72 ALDH1A1 (0.60) POLBL3MBTL1KDM4EUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932343-B2 Fused tricyclic benzimidazoles derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2018-04-03 US disclosed
US-20160304523-A1 Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity SANOFI (FR) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304523-A1 Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity TNF, TNFRSF1A, TNFRSF9 POLB 1132/4885TP53 834/4885L3MBTL1 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.